After losing $30 billion in market value, Bristol-Myers Squibb Co. is starting to hear buyout drums.Activist investors are circling, with both Jana Partners and Carl Icahn recently taking stakes in the drugmaker. The latter believes the company is a potential acquisition target, The Wall Street Journal reported on Tuesday.
